PM
Prosight Management Portfolio holdings
AUM
$410M
This Quarter Return
+37.02%
1 Year Return
-14.96%
3 Year Return
+21.81%
5 Year Return
+1.17%
10 Year Return
–
AUM
$219M
AUM Growth
+$219M
(+22%)
Cap. Flow
-$10.4M
Cap. Flow
% of AUM
-4.76%
Top 10 Holdings %
Top 10 Hldgs %
60.99%
Holding
47
New
12
Increased
12
Reduced
11
Closed
10
Top Buys
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$7.49M |
| 2 |
Envista
NVST
|
$4.89M |
| 3 |
AnaptysBio
ANAB
|
$3.82M |
| 4 |
Aldeyra Therapeutics
ALDX
|
$3.71M |
| 5 |
MeiraGTx Holdings
MGTX
|
$3.6M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$19.1M |
| 2 |
HNGR
Hanger Inc.
HNGR
|
$8.05M |
| 3 |
uniQure
QURE
|
$6.56M |
| 4 |
UroGen Pharma
URGN
|
$3.59M |
| 5 |
Humana
HUM
|
$3.07M |
Sector Composition
| 1 | Healthcare | 98.09% |
| 2 | Industrials | 1.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$21B
| $19.5M | 8.54% | 130,000 +2,000 | +2% | +$299K |
|
|
2
uniQure
QURE
$896M
| $17M | 7.47% | 237,500 -91,478 | -28% | -$6.56M |
|
|
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $14.9M | 6.54% | 328,129 +164,996 | +101% | +$7.49M |
|
4
Kura Oncology
KURA
$686M
| $14.2M | 6.25% | 1,036,000 +147,848 | +17% | +$2.03M |
|
5
United Therapeutics
UTHR
$13.8B
| $14.2M | 6.23% | 161,195 +28,258 | +21% | +$2.49M |
|
|
RETA
6
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $12.9M | 5.65% | 62,900 +309 | +0.5% | +$63.2K |
|
7
Iovance Biotherapeutics
IOVA
$807M
| $10.8M | 4.72% | 388,600 +42,451 | +12% | +$1.17M |
|
8
AC Immune
ACIU
$205M
| $10.6M | 4.65% | 1,242,843 -5,610 | -0.4% | -$47.8K |
|
|
9
MeiraGTx Holdings
MGTX
$587M
| $10.4M | 4.55% | 517,844 +179,748 | +53% | +$3.6M |
|
|
ARQL
10
DELISTED
Arqule Inc
ARQL
| $8.99M | 3.95% | 450,326 +85,529 | +23% | +$1.71M |
|
11
Centene
CNC
$14.3B
| $8.98M | 3.94% | 142,800 -22,200 | -13% | -$1.4M |
|
|
12
Aldeyra Therapeutics
ALDX
$351M
| $8.3M | 3.64% | 1,428,277 +638,049 | +81% | +$3.71M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.2B
| $7.84M | 3.44% | 92,737 +2,785 | +3% | +$235K |
|
|
14
UroGen Pharma
URGN
$900M
| $7.26M | 3.19% | 217,686 -107,699 | -33% | -$3.59M |
|
|
ALBO
15
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $6.28M | 2.76% | 247,178 -5,322 | -2% | -$135K |
|
|
16
Envista
NVST
$3.52B
| $4.89M | 2.15% | +165,000 | New | +$4.89M |
|
17
Personalis
PSNL
$434M
| $4.43M | 1.95% | 406,673 +291,459 | +253% | +$3.18M |
|
|
18
AnaptysBio
ANAB
$569M
| $3.82M | 1.68% | +234,823 | New | +$3.82M |
|
19
Immunovant
IMVT
$2.56B
| $3.57M | 1.57% | +224,702 | New | +$3.57M |
|
20
Organogenesis Holdings
ORGO
$653M
| $2.97M | 1.3% | +617,836 | New | +$2.97M |
|
21
Evolus
EOLS
$494M
| $2.88M | 1.27% | +236,939 | New | +$2.88M |
|
22
Gyre Therapeutics
GYRE
$703M
| $2.67M | 1.17% | 391,894 -166,265 | -30% | -$1.13M |
|
|
SBBP
23
DELISTED
Strongbridge Biopharma plc.
SBBP
| $2.63M | 1.15% | 1,258,224 -1,256,848 | -50% | -$2.63M |
|
|
RCM
24
DELISTED
R1 RCM Inc. Common Stock
RCM
| $2.6M | 1.14% | 200,000 -208,958 | -51% | -$2.71M |
|
25
Evolent Health
EVH
$1.12B
| $2.53M | 1.11% | +279,390 | New | +$2.53M |
|